Merck Victrelis Glowing Recommendation From NICE At Odds With IQWiG
This article was originally published in The Pink Sheet Daily
The contrasting views in Germany and England for the hepatitis C product underscore the difference between IQWiG’s purely scientific assessment and NICE’s focus on cost-effectiveness.
You may also be interested in...
Gilead’s high-cost hepatitis C drug is surprisingly close to making it through U.K.’s cost-effectiveness watchdog.
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.